Clinical trial nabs SEC attention

Share this article:

A Securities and Exchange Commission investigation has added a new angle to the clinical trial world: the potential for insider trading. The government agency announced Monday that it has accused two California doctors of illegally using non-public information to make money.

The SEC says the two doctors had agreed to provide services as part of a clinical trial for GTx, which was testing its prostate cancer drug Capesaris. The doctors were paid for their participation in the study, and the SEC notes the contracts “contained strict confidentiality provisions” that kept the physicians from “using non-public information about the trials for any purpose other than rendering services.”

The SEC alleges that the doctors sold GTx stock after the drugmaker said the FDA idled the trials over safety concerns, and before GTx made this news public. The SEC says the doctors saved close to a combined $46,000 because they were able to unload stock before the news depressed share prices.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies